Rheumatoid Arthritis Drugs Market Worth $30.4 Billion By 2025

February 2018 | Report Format: Electronic (PDF)

The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth. 

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of disease remittance.

 To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market

Further key findings from the report suggest:

  • North America held 56.6% of the market in 2016 due to rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment

  • Due to growing popularity, the biopharmaceuticals segment is projected to exhibit a CAGR of 8.3% during the forecast period

  • Prescriptions are anticipated to emerge as more reliable and a preferred sales channel over the same period

  • Asia Pacific is the most promising region, registering a CAGR of 9.5% between 2017 and 2025

  • Some of the key players in rheumatoid arthritis market are AbbVie; Boehringer Ingelheim GmbH; Novartis AG; Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; UCB S.A.; Johnson & Johnson Services, Inc.; and Amgen, Inc.

Grand View Research has segmented the rheumatoid arthritis drugs/therapeutics market on the basis of molecule types, sales channels, and region:

Rheumatoid Arthritis Therapeutics Molecule Outlook (Revenue, USD Million, 2014 - 2025)

  • Pharmaceuticals

    • NSAIDs

    • Analgesics

    • DMARDs

    • Glucocorticoids

  • Biopharmaceuticals

    • Biologics

      • TNF-α antagonists

      • T-cell inhibitors

      • CD20 antigen

      • JAK inhibitors

      • anti-IL6 biologics

    • Biosimilars

      • CD20 antigen

      • TNF-α antagonists

Rheumatoid Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2014 - 2025)

  • Prescription

  • Over-the-Counter (OTC)

Rheumatoid Arthritis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

Request Sample
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA